|Bid||4.1300 x 4000|
|Ask||4.1700 x 3200|
|Day's Range||4.1200 - 4.3950|
|52 Week Range||3.5000 - 10.4500|
|Beta (3Y Monthly)||1.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.48|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...
Akebia Therapeutics, Inc. (AKBA), a fully integrated biopharmaceutical company focused on bettering the lives of people impacted by kidney disease, today filed a complaint in federal district court against the Centers for Medicare & Medicaid Services (CMS) and the U.S. Department of Health and Human Services (HHS). The lawsuit challenges a September 2018 decision by CMS that rescinded Medicare Part D coverage of Auryxia® (ferric citrate), Akebia’s FDA-approved drug, when used for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) not on dialysis (the IDA Indication).
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted seven newly-hired employees options to purchase an aggregate of 43,600 shares of Akebia’s common stock on September 30, 2019, as inducements material to each such employee’s entering into employment with Akebia. The options have an exercise price of $3.92 per share, which is equal to the closing price of Akebia’s common stock on the grant date. Each stock option vests over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% of shares vesting quarterly thereafter, in each case, subject to the new employee’s continued service with the company.
John Butler became the CEO of Akebia Therapeutics, Inc. (NASDAQ:AKBA) in 2013. This report will, first, examine the...
Akebia Therapeutics, Inc. (AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that John P. Butler, President and Chief Executive Officer of Akebia, will present at the 2019 Cantor Global Healthcare Conference at 8:55 a.m. ET on Thursday, October 3, 2019 in New York City. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease.
If you own shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA) then it's worth thinking about how it contributes to the...
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 14.29% and 14.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The big shareholder groups in Akebia Therapeutics, Inc. (NASDAQ:AKBA) have power over the company. Institutions often...
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the...
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
AkebiaCares connects patients, caregivers and health care providers with resources and important information to support greater access to therapy